Value of immunogenicity in the TNF-α inhibitor treatment of rheumatic diseases
Immunogenicity, the characteristic property of proteins affecting an immune response, shows up in the formation of anti-drug antibodies (ADA) and/or immune complexes. The paper discusses whether immunogenicity has an impact on the efficacy and safety of TNF-α inhibitors (TNF-αI) in different rheumat...
Saved in:
Main Author: | N. V. Chichasova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2016-01-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/647 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients
by: Mateusz Makuch, et al.
Published: (2025-07-01) -
Commentary: Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
by: Yingjie Liu, et al.
Published: (2025-07-01) -
Efficacy of tumor necrosis factor-α inhibitors in the treatment of various immunoinflammatory diseases: focus on immunogenicity
by: T. Yu. Nuriahmetova, et al.
Published: (2023-08-01) -
Development and Validation of the Cell-based Functional Method for Neutralizing Anti-adalimumab Antibodies Detection in Human Serum
by: M. A. Nikiforova, et al.
Published: (2024-03-01) -
Treatment of ankylosing spondylitis during pregnancy
by: O. A. Krichevskaya, et al.
Published: (2021-07-01)